Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
2020; Elsevier BV; Volume: 83; Issue: 5 Linguagem: Inglês
10.1016/j.jaad.2020.04.054
ISSN1097-6787
AutoresDiego Fernández‐Nieto, David Saceda‐Corralo, Juan Jimenez‐Cauhe, Óscar Muñoz Moreno-Arrones, Rita Rodrigues‐Barata, Ángela Hermosa‐Gelbard, Sergio Vañó‐Galván,
Tópico(s)Male Breast Health Studies
ResumoTo the Editor: We read with interest the recent article by Ferial Ismail et al1 reporting the safety and efficacy of oral bicalutamide (OB) in 316 patients with female pattern hair loss (FPHL).1 FPHL is associated with an increased androgen action in the scalp. Classic antiandrogen therapies such as spironolactone, cyproterone acetate, and flutamide can improve FPHL. OB is a selective androgen receptor antagonist with a higher affinity and a better safety profile than flutamide.2 This makes OB a promising treatment for FPHL and other androgen-related conditions such as seborrhea, acne, and hirsutism.
Referência(s)